Newsfeeds - Spark Newswire

1 minute read

Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment

Today, 9:04 AM

Seagen Inc (NASDAQ:SGEN) and Zai Lab Limited (NASDAQ:ZLAB) have announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK…

GMAB

1 minute read

Golden Cross Appears Before Genmab Investors

By Benzinga Insights

Today, 9:04 AM

If history is any guide, there may be good fortune ahead for shares of Genmab (NASDAQ:GMAB). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

GMAB

1 minute read

HC Wainwright Is Bullish On This Multiple Myeloma Focused Stock

By Vandana Singh

Today, 9:04 AM

HC Wainwright increased the price target on Genmab A/S (NASDAQ:GMAB) from $49 to $51, with a Buy rating. The analyst cites that…

GMAB

1 minute read

Uncategorized

Genmab Reports H1 2022 Net Sales Of DARZALEX By Janssen Were $3.842B

By Benzinga Newsdesk

Today, 9:04 AM

Financial Performance First Half of 2022 Net sales of DARZALEX by Janssen were USD 3,842 million in the first six months of 2022 compared to USD 2,798 million in the first six months of 2021, an increase of

GMAB

2 minute read

Genmab and BioNTech Expand Global Collaboration To Include Development Of Monospecific Antibody Candidates To Address Malignant Solid Tumors

By Bill Haddad

Today, 9:04 AM

Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors Expanded collaboration leverages Genmab's proprietary HexaBody® technology platform to

BNTX

1 minute read

HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $49

By Benzinga Newsdesk

Today, 9:04 AM

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $47 to $49.

GMAB

1 minute read

AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022

By Vandana Singh

Today, 9:04 AM

Genmab A/S (NASDAQ:GMAB) has announced that AbbVie Inc (NASDAQ:ABBV) will submit a conditional marketing authorization application with the European Medicines Agency…

ABBV